Evidence map›Paper›PMID 42646749›Full record

ArticleToxins2026

Transcriptional Profiling of Botulinum Neurotoxin Type A-Related Molecular Components in Primary Human Schwann Cells.

Oscar Sánchez-Carranza, Claudia Jatzke, Andreas Gravius, Jens Nagel

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Oscar Sánchez-CarranzaMerz Therapeutics GmbH, Eckenheimer Landstraße 100, 60318 Frankfurt am Main, Germany.
Claudia JatzkeMerz Therapeutics GmbH, Eckenheimer Landstraße 100, 60318 Frankfurt am Main, Germany.
Andreas GraviusMerz Therapeutics GmbH, Eckenheimer Landstraße 100, 60318 Frankfurt am Main, Germany.
Jens NagelMerz Therapeutics GmbH, Eckenheimer Landstraße 100, 60318 Frankfurt am Main, Germany.ORCID 0000-0001-9044-3638

Funding

Merz Therapeutics GmbH n.a.
6 · The paper itself

Abstract

Schwann cells (SC) myelinate peripheral axons and orchestrate nerve regeneration after injury by switching between myelinating, proliferative and repair states. Evidence suggests that Botulinum Neurotoxin Type A (BoNT/A) influences SC biology, potentially supporting nerve repair and pain relief in peripheral neuropathic pain (PNP) models. However, BoNT/A receptor and target expression in human SC (hSC) remains poorly explored. Here, this translational gap was addressed by transcriptionally profiling genes encoding BoNT/A-relevant receptors and targets in primary hSC and testing whether paclitaxel evokes hSC phenotype plasticity in vitro based on changes in gene expression. Primary hSC were isolated, cultured, and treated with paclitaxel or vehicle, followed by RT-qPCR profiling of hSC markers and BoNT/A receptor/targets genes. Untreated hSC expressed moderate

Indexed as

Botulinum Toxins, Type ASchwann CellsCells, CulturedGene Expression ProfilingHumansMembrane GlycoproteinsNerve Tissue ProteinsPaclitaxelReceptors, Nerve Growth FactorSynaptosomal-Associated Protein 25Synaptotagmin IBotulinum Toxins, Type AMembrane GlycoproteinsNerve Tissue ProteinsNGFR protein, humanPaclitaxelReceptors, Nerve Growth FactorSNAP25 protein, humanSynaptosomal-Associated Protein 25Synaptotagmin IBoNT/Abotulinum neurotoxinhumanpaclitaxelpainSchwann cells

Identifiers

PMID42646749
PMCPMC13517366

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.